Dilemma in management of hemorrhagic myositis in dermatomyositis.
Compression Bandages
Conservative Treatment
Dermatomyositis
/ complications
Drainage
Enzyme Inhibitors
/ therapeutic use
Female
Glucocorticoids
/ therapeutic use
Hematoma
/ diagnostic imaging
Hemorrhage
/ diagnostic imaging
Hemostasis, Surgical
Humans
Hypotension
/ etiology
Immunoglobulins, Intravenous
/ therapeutic use
Immunologic Factors
/ therapeutic use
Methylprednisolone
/ therapeutic use
Middle Aged
Mortality
Muscular Diseases
/ diagnostic imaging
Mycophenolic Acid
/ therapeutic use
Pectoralis Muscles
/ diagnostic imaging
Prednisone
/ therapeutic use
Quadriceps Muscle
Dermatomyositis complications
Hematoma
Hemorrhage
Myositis
Journal
Rheumatology international
ISSN: 1437-160X
Titre abrégé: Rheumatol Int
Pays: Germany
ID NLM: 8206885
Informations de publication
Date de publication:
Feb 2020
Feb 2020
Historique:
received:
16
09
2019
accepted:
11
12
2019
pubmed:
25
12
2019
medline:
10
2
2021
entrez:
25
12
2019
Statut:
ppublish
Résumé
Dermatomyositis (DM) is a rare inflammatory disorder affecting the muscle and skin. DM patients can present with spontaneous muscle hemorrhage, a potentially fatal complication. The best practice for management of hemorrhagic myositis in these patients remains unclear. Here we discuss the case of a patient who presented with progressive muscle weakness and intermittent rash that was diagnosed with dermatomyositis. During admission, she developed spontaneous hemorrhagic myositis of the right pectoralis major treated with surgical evacuation. She also developed a spontaneous left anterior thigh hematoma which was treated conservatively. She recovered and showed no evidence of recurrent bleeding at either location. We performed a literature review and identified ten cases of spontaneous hemorrhage in DM patients, with a 60% mortality rate among reported cases. Given the high mortality rate associated with spontaneous hemorrhage in DM patients, it is important for physicians to be aware of the diagnosis, workup, and management strategies.
Identifiants
pubmed: 31872270
doi: 10.1007/s00296-019-04501-7
pii: 10.1007/s00296-019-04501-7
doi:
Substances chimiques
Enzyme Inhibitors
0
Glucocorticoids
0
Immunoglobulins, Intravenous
0
Immunologic Factors
0
Mycophenolic Acid
HU9DX48N0T
Prednisone
VB0R961HZT
Methylprednisolone
X4W7ZR7023
Types de publication
Case Reports
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
331-336Références
Mod Rheumatol. 2010 Aug;20(4):420-2
pubmed: 20376685
Ann Rheum Dis. 2004 Apr;63(4):464-5
pubmed: 15020349
Ther Clin Risk Manag. 2018 Jan 23;14:157-165
pubmed: 29416342
Arch Dermatol. 2010 Jan;146(1):26-30
pubmed: 20083689
Muscle Nerve. 1998 Dec;21(12):1800-3
pubmed: 9843089
Clin Exp Dermatol. 2009 Apr;34(3):448-9
pubmed: 19309387
Case Rep Rheumatol. 2014;2014:639756
pubmed: 25379317
Ann Rheum Dis. 2009 Jul;68(7):1192-6
pubmed: 18713785
Arterioscler Thromb Vasc Biol. 2003 Dec;23(12):2131-7
pubmed: 14500287
Intern Med. 2015;54(8):995-6
pubmed: 25876592
Rheumatol Int. 2009 Sep;29(11):1363-6
pubmed: 19089428
Diagn Interv Imaging. 2015 Jul-Aug;96(7-8):789-96
pubmed: 26066549
Rheumatol Int. 2013 Nov;33(11):2949-50
pubmed: 22865055
Emerg Med Int. 2019 Feb 21;2019:2406873
pubmed: 30923638
Cardiovasc Intervent Radiol. 2019 Mar;42(3):335-343
pubmed: 30327927
Curr Dir Autoimmun. 2008;10:313-32
pubmed: 18460893
Mod Rheumatol. 2019 Jan;29(1):1-19
pubmed: 30565491